Judge orders RFK Jr.'s health department to stop sharing Medicaid data with deportation officials
The U.S. Department of Health and Human Services first handed over the personal data on millions of Medicaid enrollees in a handful of states in June. After an Associated Press report identified the new policy, 20 states filed a lawsuit to stop its implementation.
In July, the Centers for Medicare and Medicaid Services entered into a new agreement that gave the Department of Homeland Security daily access to view the personal data — including Social Security numbers and home address — of all the nation's 79 million Medicaid enrollees. Neither agreement was announced publicly.
The extraordinary disclosure of such personal health data to deportation officials in the Trump administration's far-reaching immigration crackdown immediately prompted the lawsuit over privacy concerns.
The Medicaid data sharing is part of a broader effort by the Trump administration to provide DHS with more data on migrants. In May, for example, a federal judge refused to block the Internal Revenue Service from sharing immigrants' tax data with Immigration and Customs Enforcement to help agents locate and detain people living without legal status in the U.S.
The order, issued by federal Judge Vince Chhabria in California, temporarily halts the health department from sharing personal data of enrollees in those 20 states, which include California, Arizona, Washington and New York.
'Using CMS data for immigration enforcement threatens to significantly disrupt the operation of Medicaid—a program that Congress has deemed critical for the provision of health coverage to the nation's most vulnerable residents,' Chhabria wrote in his decision, issued on Tuesday.
Chhabria, an appointee of President Barack Obama, said that the order will remain in effect until the health department outlines 'reasoned decisionmaking' for its new policy of sharing data with deportation officials.
A spokesperson for the federal health department declined to directly answer whether the agency would stop sharing its data with DHS. HHS has maintained that its agreement with DHS is legal.
Immigrants who are not living in the U.S. legally, as well as some lawfully present immigrants, are not allowed to enroll in the Medicaid program that provides nearly free coverage for health services. But federal law requires all states to offer emergency Medicaid, a temporary coverage that pays only for lifesaving services in emergency rooms to anyone, including non-U.S. citizens. Medicaid is a jointly funded program between states and the federal government.
Immigration advocates have said the disclosure of personal data could cause alarm among people seeking emergency medical help for themselves or their children. Other efforts to crack down on illegal immigration have made schools, churches, courthouses and other everyday places feel perilous to immigrants and even U.S. citizens who fear getting caught up in a raid.
'Protecting people's private health information is vitally important,' Washington state's Attorney General Nick Brown said in a statement. 'And everyone should be able to seek medical care without fear of what the federal government may do with that information.'
___
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
8 hours ago
- Winnipeg Free Press
4th person dies after a Legionnaires' disease outbreak sickens dozens in New York City
NEW YORK (AP) — A fourth person has died in connection with a Legionnaires' disease outbreak in New York City, health officials disclosed Thursday as they revealed that some cooling towers that tested positive for the bacteria are in city-run buildings. The outbreak in Central Harlem has sickened dozens since it began in late July. Seventeen people were hospitalized as of Thursday, according to the health department. The bacteria that causes Legionnaires' disease had been discovered in 12 cooling towers on 10 buildings, including a city-run hospital and sexual health clinic, health officials said. Remediation efforts have been completed on 11 of the cooling towers, with the final tower's remediation required to be completed Friday. Legionnaires' disease is a type of pneumonia that is caused by Legionella bacteria, which grow in warm water and spread through building water systems. The city's outbreak has been linked to cooling towers, which use water and a fan to cool buildings. Wednesdays What's next in arts, life and pop culture. People usually develop symptoms — a cough, fever, headaches, muscle aches and shortness of breath — between two days to two weeks after exposure to the bacteria, according to the U.S. Centers for Disease Control and Prevention. Dr. Michelle Morse, the city's acting health commissioner, said new cases in the Central Harlem outbreak have begun to decline 'which indicates that the sources of the bacteria have been contained.' She urged people who live or work in the area to contact a health care provider if they develop flu-like symptoms.
Toronto Star
9 hours ago
- Toronto Star
4th person dies after a Legionnaires' disease outbreak sickens dozens in New York City
NEW YORK (AP) — A fourth person has died in connection with a Legionnaires' disease outbreak in New York City, health officials disclosed Thursday as they revealed that some cooling towers that tested positive for the bacteria are in city-run buildings. The outbreak in Central Harlem has sickened dozens since it began in late July. Seventeen people were hospitalized as of Thursday, according to the health department.
Globe and Mail
12 hours ago
- Globe and Mail
Eli Lilly hikes price of Mounjaro weight-loss drug in Canada, Britain after pressure from Trump
U.S. drugmaker Eli Lilly & Co. has increased prices of its popular diabetes and anti-obesity drugs in Canada as it responds to pressure from the Trump administration to lower prices in the United States and raise them elsewhere. The company also announced it is sharply raising prices in Britain to match those in other European markets. The moves make the company one of the most high-profile so far to respond U.S. President Donald Trump's direction to rebalance global drug prices. 'Lilly supports the administration's goal of keeping the United States the world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries,' the company said Thursday in an unsigned statement. 'This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the U.S.' Is working out necessary in the age of Ozempic? Lilly is raising the list price in Britain for Mounjaro, its type 2 diabetes treatment, by 170 per cent, Reuters reported. The market for weight-loss drugs has exploded in recent years, led by Novo Nordisk's Ozempic and Wegovy, which are prescribed for diabetes and obesity, respectively. Ozempic earned $2.5-billion at retail pharmacies in Canada in 2024, according to data from industry broker IQVIA, nearly triple the next best-selling drug. Lilly introduced Mounjaro in Canada in late 2023. It was originally sold in single-dose vials (taken weekly) at a wholesale price of around $80. It is sold in six different dosages. The company then introduced a four-dose format called Kwikpen in January of 2025 and then a Kwikpen form of Zepbound, for obesity, in June. At the same time, it raised the prices of the single-dose vials to be in line with those of the Kwikpen and lowered production of the vials, leading to low inventories across the country. Cubic Health, a company that analyzes drug prices for insurance plan sponsors, said in a recent note to its clients that the annual cost of taking Mounjaro has more than doubled for high dosages since it first came to Canada. Cubic said the wholesale price for the Kwikpen now ranges from $387 to $773 depending on dosage, which can lead to an annual cost of more than $10,000. (Individual costs can vary depending on pharmacy, insurance coverage, discounts and other factors.) 'Vials were only intended as a short-term solution until a multidose pen became available to the Canadian market,' Lilly spokesman Ethan Pigott said in a statement. 'Lilly will continue to support patients already using the vial format, but the KwikPen device will be prioritized go-forward for its supply sustainability, ease of use and multidose presentation.' He also said discussion of price should include multiple factors. 'Both Mounjaro and Zepbound are priced to reflect the value they can provide to individuals, health systems, and society in treating type 2 diabetes and obesity,' Mr. Pigott said. Mounjaro and Zepbound are covered by some private insurance plans, depending on individual plan designs. The drugs are not yet covered by any public insurance plans, which require going through national bodies that assess drugs and negotiate prices. Lilly had started an application to Canada's Drug Agency to have Mounjaro (also known as tirzepatide) assessed in 2022, but a spokesperson for the CDA said the submission was cancelled because of paperwork deficiencies. Earlier: Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers Mr. Pigott said Lilly is finalizing plans to resubmit Mounjaro, along with Zepbound, to the CDA 'in 2025.' While the average cost of these drugs in Canada is up, it is still a little short of prices in the U.S. The wholesale price of Zepbound in the U.S. is US$1,086, according to Lilly's website. It also offers direct-to-consumer sales in the U.S. at prices that range from US$349 to US$1,049, depending on dosage. Lilly has not yet launched direct sales in Canada. Drug prices in the U.S. are, on average, more than three times those in Canada. Mr. Trump has repeatedly mentioned that statistic as he admonishes drug companies for their prices. In May, he signed an executive order that directed Health Secretary Robert F. Kennedy Jr. to work with drug companies on 'most favoured nation' pricing for pharmaceuticals. Trump says new order will lower U.S. drug prices and increase them everywhere else Two weeks ago, Mr. Trump sent letters to 17 drug companies – including Lilly – telling them to increase prices in non-U.S. markets to make up for lower revenue in the U.S. The administration has also launched a national-security investigation of the sector that could lead to tariffs, which Mr. Trump has mused could be as high as 200 per cent. In Lilly's statement on Thursday, the company said it does not support tariffs. 'Broad tariffs would raise costs, limit patient access and undermine American leadership, especially for companies already investing heavily in domestic manufacturing,' the company said.
